Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Indometacin farnesil
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration |
Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | To indometacin |
Elimination half-life | 1.5 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.242.585 |
Chemical and physical data | |
Formula | C34H40ClNO4 |
Molar mass | 562.15 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Indometacin farnesil (INN) is a prodrug of the nonsteroidal anti-inflammatory drug (NSAID) indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon, respectively.
External links
- Infree (indometacin farnesil capsules) Full Prescribing Information Archived 2010-12-03 at the Wayback Machine from Eisai Co.
pyrazolones / pyrazolidines |
|
---|---|
salicylates | |
acetic acid derivatives and related substances |
|
oxicams | |
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) |
|
COX-2 inhibitors (coxibs) |
|
other | |
NSAID combinations |
|
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |